The lancet 4.2022 Cancer care: beyond survival, Improved models of care for cancer survivors https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00306-3/fulltext facts: IOM stated survivorship care agenda: 1. reduce recurrence, new cancer and late effects from Tx 2. survellance 3. Side effect management 4. Coordination with PCP Take-home: Routine holistic assessment of needs NEJM 4.14/2022 Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 Pfizer drug facts: 1. nirmatrelvir plus ritonavir risk reduction 89%, symptomatic high risk covid-19 take-home: Another pfizer antiviral? still has drug interaction issue. 和现在的Paxlovid 差不多。 |